Catch up on the top radiology content of the past week.
|Articles|January 21, 1998
Elscint names Sardano to NM post
Israeli multimodality vendor Elscint has named Joe Sardano head of its U.S. nuclear medicine business unit, a position that previously had been vacant. Prior to joining Elscint in November, Sardano was with Fisher Scientific, and has also worked for
Advertisement
Israeli multimodality vendor Elscint has named Joe Sardano head of its U.S. nuclear medicine business unit, a position that previously had been vacant. Prior to joining Elscint in November, Sardano was with Fisher Scientific, and has also worked for Park, Toshiba, and Diasonics. Sardano said his priorities in the position are to expand Elscint's sales force, broaden the company's marketing efforts, and improve the vendor's customer satisfaction levels in the U.S.
Sardano will report to Eliezer Tokman, the Elscint CT veteran who was named to head the company's Americas regional operations in a restructuring announced in November (SCAN 11/12/97). Elscint is moving its global nuclear medicine headquarters to the U.S. as part of the restructuring.
Advertisement
Related to this article
While a new article raises provocative questions about the capability of photon-counting CT (PCCT) to perhaps replace diagnostic ICA, the real revolution with this modality is going beyond stenosis measurement to a renewed focus on the disease of atherosclerosis.
The use of adjunctive CT bone reading software in women with breast cancer detected between 8 to 22 percent more metastatic lesions for reviewing radiologists and reduced CT interpretation time by 50 percent or more, according to a new study.
Catch up on the top radiology content of the past week.
Catch up on the top radiology content of the past week.
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Magnetic resonance imaging offered a 29 percent higher sensitivity than CT for differentiating liver metastases, but CT provided 12 percent higher sensitivity than MRI for assessing vascular invasion, according to a new 40-study meta-analysis.
Does fractional flow reserve (FFR) or quantitative plaque burden from CCTA provide greater prognostic insight into coronary disease?
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears MRI-Based AI Software for Prognostic Evaluation of Patients with Mild Cognitive Impairment
2
Can MRI-Based AI Have an Impact in Reducing Unnecessary Prostate Biopsies?
3
The Reading Room Podcast: A Closer Look at New Research on 177Lu-Edotreotide for Treating GEP-NETs
4
How AI, Theranostics and More Empowered Patients Have Led to Significant Changes in Radiology
5